Trastuzumab botidotin - Klus Pharma
Alternative Names: A-166Latest Information Update: 28 Oct 2026
At a glance
- Originator Klus Pharma
- Developer Klus Pharma; Sichuan Kelun-Biotech Biopharmaceutical
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Tubulin polymerisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered HER2 positive breast cancer
- Phase I/II Solid tumours
- No development reported Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Urogenital cancer
Most Recent Events
- 28 Oct 2026 Sichuan Kelun-Biotech Biopharmaceutical completes the Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (IV) before October 2019 (CTR20181301) (NCT05311397)
- 14 Sep 2026 Adverse events and efficacy data from a phase-III trial in Breast cancer released by Sichuan Kelun-Biotech Biopharmaceutical
- 28 Nov 2025 No recent reports of development identified for phase-I development in Adenocarcinoma(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral, Injection)